Literature DB >> 16954426

Pituitary tumours: findings from whole genome analyses.

W E Farrell1.   

Abstract

Pituitary tumours are common intracranial neoplasms that cause significant morbidity through mass effects and/or the inappropriate secretion of pituitary hormones. Despite a considerable literature detailing potential pathogenic changes in these tumours, their aetiology remains largely unresolved. Recent studies have employed genome-wide profiling towards the identification of novel genes and pathways that are inappropriately expressed or regulated in this tumour type. The techniques employed vary in their complexity and interpretation; however, many of the findings from these types of studies have identified novel genes with potential and, in some cases, proven roles in pituitary tumorigenesis. These studies include comparative genomic hybridization, whole genome-wide allelotyping and methodologies for identification of novel genes associated with epigenetic silencing. In addition, differential display methodologies have been instrumental in the identification of transcripts inappropriately expressed including, pituitary tumour transforming gene, growth arrest and DNA damage-inducible protein (GADD)45gamma and a maternal expressed gene 3 isoform, which in some cases have proven roles in pituitary tumorigenesis. Although few studies of whole genome transcript analysis, as determined by microarray or gene-chip technologies, are reported, these studies of human pituitary, in some cases combined with proteomics, are yielding useful data. In addition, these types of investigation have been applied to several animal models of pituitary tumorigenesis, and in these cases novel genes are highlighted as showing significant change. The identification of the initiating events responsible for the transformation of a normal pituitary cell into one with unrestrained proliferative capacity has so far eluded us. No doubt, these new technologies allowing an essentially unbiased genome-wide analysis, perhaps in combination with animal models that display a preceding hyperplasia, will allow us to identify genes critical to tumour evolution and progression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16954426     DOI: 10.1677/erc.1.01131

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  17 in total

1.  The clinical significance of MIB-1 labeling index in pituitary adenomas.

Authors:  Geeta Chacko; Ari G Chacko; Kalman Kovacs; Bernd W Scheithauer; Sunithi Mani; J P Muliyil; M S Seshadri
Journal:  Pituitary       Date:  2010-12       Impact factor: 4.107

Review 2.  Pathogenesis of pituitary tumors.

Authors:  Shlomo Melmed
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

Review 3.  The pituitary TGFβ1 system as a novel target for the treatment of resistant prolactinomas.

Authors:  M Victoria Recouvreux; M Andrea Camilletti; Daniel B Rifkin; Graciela Díaz-Torga
Journal:  J Endocrinol       Date:  2015-12-23       Impact factor: 4.286

4.  Loss of function of the tumor suppressor DKC1 perturbs p27 translation control and contributes to pituitary tumorigenesis.

Authors:  Cristian Bellodi; Olya Krasnykh; Nikesha Haynes; Marily Theodoropoulou; Guang Peng; Lorenzo Montanaro; Davide Ruggero
Journal:  Cancer Res       Date:  2010-06-29       Impact factor: 12.701

Review 5.  Pituitary senescence: the evolving role of Pttg.

Authors:  Vera Chesnokova; Shlomo Melmed
Journal:  Mol Cell Endocrinol       Date:  2010-02-12       Impact factor: 4.102

6.  p21(Cip1) restrains pituitary tumor growth.

Authors:  Vera Chesnokova; Svetlana Zonis; Kalman Kovacs; Anat Ben-Shlomo; Kolja Wawrowsky; Serguei Bannykh; Shlomo Melmed
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-03       Impact factor: 11.205

Review 7.  Acromegaly pathogenesis and treatment.

Authors:  Shlomo Melmed
Journal:  J Clin Invest       Date:  2009-11-02       Impact factor: 14.808

Review 8.  Familial isolated pituitary adenomas: an emerging clinical entity.

Authors:  F Martucci; G Trivellin; M Korbonits
Journal:  J Endocrinol Invest       Date:  2012-12       Impact factor: 4.256

9.  Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas.

Authors:  Roger Gejman; Dalia L Batista; Ying Zhong; Yunli Zhou; Xun Zhang; Brooke Swearingen; Constantine A Stratakis; E Tessa Hedley-Whyte; Anne Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2008-07-15       Impact factor: 5.958

10.  Genetics, gene expression and bioinformatics of the pituitary gland.

Authors:  Shannon W Davis; Mary Anne Potok; Michelle L Brinkmeier; Piero Carninci; Robert H Lyons; James W MacDonald; Michelle T Fleming; Amanda H Mortensen; Noboru Egashira; Debashis Ghosh; Karen P Steel; Robert Y Osamura; Yoshihide Hayashizaki; Sally A Camper
Journal:  Horm Res       Date:  2009-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.